The orexin/hypocretin system : physiology and pathophysiology /

Saved in:
Bibliographic Details
Imprint:Totowa, N.J. : Humana Press, c2005.
Description:1 online resource (xii, 397 p.) : ill.
Language:English
Series:Contemporary clinical neuroscience
Contemporary clinical neuroscience.
Subject:
Format: E-Resource Book
URL for this record:http://pi.lib.uchicago.edu/1001/cat/bib/8877324
Hidden Bibliographic Details
Other authors / contributors:Nishino, Seiji.
Sakurai, Takeshi.
ISBN:1588294447 (alk. paper)
9781588294449 (alk. paper)
9781592599509
1592599508
Notes:Includes bibliographical references and index.
Mode of access: Internet.
Description based on print version record.
Summary:This cutting-edge review of the orexin/hypocretin system sets the stage for advanced research on the pathological mechanisms underlying the loss of orexin/hypocretin neurons in humans, regulation of sleep and wakefulness by the orexin/hypocretin system, and the role of the orexin/hypocretin system in many other physiological processes, including feeding, autonomic regulation, and neuroendocrine regulation. Topics of interest include assessment of functions and the physiology of orexin/hypocretin, its pathophysiology in human narcolepsy-cataplexy, and possible treatments and pharmacology. The a.
Other form:Orexinhypocretin system : physiology and pathophysiology
Description
Summary:Orexin/hypocretin research began in 1998, as a result of the discovery of a new hypothalamic neuropeptide. In 1999, it was found that mutations in the orexin/ hypocretin-related genes caused a sleep disorder (narcolepsy) in dogs and mice. These findings were soon followed by the discoveries of orexin/hypocretin ligand deficiency in human narcolepsy. The finding of the major pathophysiological mechanisms of human narcolepsy resulted in its reclassification as a neurological, not a psychiatric, disorder. The - portance of early diagnosis and initiation of treatment for human narcolepsy has been repeatedly emphasized because the disease typically starts around puberty (when social and school influences become important). Orexin/hypocretin de- ciency in narcolepsy subjects can be detected clinically in cerebrospinal fluid (CSF) orexin/hypocretin measures (low CSF orexin/hypocretin levels are strongly asso- ated with narcolepsy-cataplexy among various neurologic and sleep disorders). Thus, the CSF orexin/hypocretin measurements are expected to be included as a diagnostic test for narcolepsy-cataplexy in the second revision of international di- nostic criteria (ICSD). This positive diagnostic test is very useful for establishing an early diagnosis for narcolepsy-cataplexy, and many patients will likely receive im- diate benefits. Cerebrospinal orexin/hypocretin measurements are also informative for the nosological classification of hypersomnia. Because orexin/hypocretin de- ciency is observed in most human narcolepsy-cataplexy, orexin/hypocretin repla- ment therapy is now a promising new choice for the treatment of human narcolepsy, and research in this area is actively in progress.
Physical Description:1 online resource (xii, 397 p.) : ill.
Format:Mode of access: Internet.
Bibliography:Includes bibliographical references and index.
ISBN:1588294447
9781588294449
9781592599509
1592599508